Quantcast

Latest Cambridge Antibody Technology Stories

2011-01-07 09:28:00

GAITHERSBURG, Md., Jan. 7, 2011 /PRNewswire/ -- MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway.

2011-01-06 15:09:00

THOUSAND OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb(®)5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b.

2010-12-07 04:00:00

BURLINGAME, Calif., Dec. 7, 2010 /PRNewswire/ -- Apexigen, Inc. announced today that it has entered into a collaboration and worldwide license agreement with Centocor Research & Development, Inc.

2010-11-22 04:30:00

THOUSAND OAKS, Calif., Nov 22, 2010 /PRNewswire/ -- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that it has received a $244,479 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA).

2010-11-16 08:00:00

GAITHERSBURG, Md., Nov. 16, 2010 /PRNewswire/ -- Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.

2010-10-18 07:00:00

PLANTATION, Fla., Oct. 18 /PRNewswire/ -- Goodwin Biotechnology, Inc., a full service contract biomanufacturing company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with a multinational biopharmaceutical client.

2010-08-12 14:50:00

BURLINGAME, Calif., Aug. 12 /PRNewswire/ -- Epitomics, Inc.

2010-08-12 11:36:00

BANNOCKBURN, Ill., Aug. 12 /PRNewswire/ -- The Board of Directors of Pinnacle Biologics Inc. has appointed Mr. James L. Foght PhD as a director of the corporation, effective July 28, 2010. Dr. Foght has over 40 years experience in the healthcare and life science industries.

2010-07-11 18:00:00

LONDON, July 12, 2010 /PRNewswire/ -- MRC Technology (UK) announced today that it has entered into an agreement with Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for an exclusive licence to a series of small molecule drug candidates for the potential treatment of neurological disease. This is the first small molecule chemistry programme to come out of MRC Technology's Centre for Therapeutics Discovery (CTD) and the first major small molecule...

2010-02-03 18:01:00

LONDON, February 4 /PRNewswire/ -- A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today. The MRCT Centre for Therapeutics Discovery (CTD), based in London, is seeking small molecule drug discovery and therapeutic antibody targets from academic researchers. The CTD would like to collaborate with scientists in all universities to develop drug...


Word of the Day
bawbee
  • A coin originally worth six pennies Scots, and later three; held equivalent to an English halfpenny.
  • (in plural) Money; cash.
Related